论文信息 - TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study - 字舞流文

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

K. Thiel | E. Devor | K. Leslie | C. Aghajanian | H. Lankes | K. Moxley | R. Soslow | V. Filiaci | C. Mathews | K. Tewari | M. Mcdonald | A. Alvarez Secord | Kristina W. Thiel | S. Dewdney | C. Cosgrove | D. Mutch | M. Samuelson